X. Long Zheng/LinkedIn
Sep 22, 2026, 07:18
X. Long Zheng: From ADAMTS13 to New TTP Treatment
X. Long Zheng, Professor and Chair of Pathology and Laboratory Medicine at The University of Kansas, shared a post on LinkedIn:
“I had a great time as a visiting professor at Montefiore Medical Center to meet with pathology residents/faculty and discuss the 100-year research and development in TTP (thrombotic thrombocytopenic purpura).
Progress has been particularly accelerated since the molecular identification and cloning of ADAMTS13, a key enzyme that is deficient in patients with TTP.
ADAMTS13 is now a FDA-approved drug for treatment of congenital TTP.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI
-
Nov 8, 2026, 07:16Gilberto de lima Lopes Junior: The Cardiovascular Consequences of Cancer in Younger Patients
-
Nov 8, 2026, 06:51Haney Mallemat: Key Principles and Pitfalls of LVAD Emergencies
-
Nov 8, 2026, 06:31Maria Omer: Clinical Recognition and Management of Cavernous Sinus Thrombosis
-
Nov 8, 2026, 06:16Natasha Jolakoski: University of New Mexico Hospital Promotes PGY-2 Thrombosis and Hemostasis Management Pharmacy Residency
-
Nov 8, 2026, 05:47Safaa Hilal: POCUS in the Evaluation of Perioperative Troponin Elevation
-
Nov 8, 2026, 05:34Eugene Bolotin: Thrombosis and Survival in Pancreatic Cancer